Fuhui Ventures
富汇创投
elsewhere's corpus does not cover Fuhui Ventures as a subject in its own right. The only mention found is a passing reference in a 2022 Gaorong Capital article, where Fuhui Ventures appeared as a follow-on investor in KSKD's Pre-A+ round . There is no entity card or dedicated coverage of its founding, team, strategy, or scale.
AI-generated — may contain errors, please verify.
Fuhui VenturesFund
富汇创投
渲染中…
Mentioned in 4 articles
Coverage
5Y News | 5Y Capital Portfolio Company "Laimang Biotech" Raises 50 Million Yuan in New Funding
Accelerating the clinical translation of ultra-low-dose CAR-T.
CDMO firm ZhiXiang Biologics raises over 500 million yuan in Series C funding to accelerate biopharma R&D for global clients
A one-stop CDMO platform for biologics R&D and manufacturing.
Global SaaS, New Brands, and Biopharma Companies Close New Funding Rounds | Rongbao · February
The vitality of spring.
Dialogue with CASI's Huaqiang Xu: "Following Nature's Way" in Drug R&D | Gaorong "Future"
CasKedy announced the completion of a nearly RMB 100 million Pre-A+ funding round.
